Starpharma (OTCMKTS:SPHRY) Shares Down 7.1% – Here’s Why

Starpharma Holdings Ltd. (OTCMKTS:SPHRY)’s stock price fell 7.1% during trading on Tuesday . The stock traded as low as $2.64 and last traded at $2.9250. 713 shares were traded during mid-day trading, an increase of 13% from the average session volume of 631 shares. The stock had previously closed at $3.15.

Starpharma Stock Down 7.1%

The company has a current ratio of 4.32, a quick ratio of 3.95 and a debt-to-equity ratio of 0.06. The business has a 50 day simple moving average of $2.85 and a two-hundred day simple moving average of $2.25.

Starpharma Company Profile

Starpharma is a clinical-stage biopharmaceutical company specializing in the development of dendrimer-based products across infectious disease, oncology and ophthalmology. Its proprietary dendrimer platform, DEP™ (Dendrimer Enhanced Products), enables precise molecular engineering to enhance drug delivery, targeting and safety profiles. The company’s lead product, VivaGel®, is a topical microbicide that has been approved in multiple markets for the treatment and prevention of bacterial vaginosis and is in clinical development for antiviral applications.

In addition to VivaGel, Starpharma is advancing pipeline candidates that leverage DEP technology to improve the performance of established and novel therapeutic agents.